

Khandan Keyomarsi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5000283/khandan-keyomarsi-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

124
papers

12,443
citations

41
h-index

111
g-index

156
ext. papers

13,342
ext. citations

9.7
avg. IF

5.89
L-index

#	Paper	IF	Citations
124	Abstract P2-05-02: Low molecular weight cyclin E facilitate replication stress tolerance in breast cancer development. <i>Cancer Research</i> , 2022 , 82, P2-05-02-P2-05-02	10.1	
123	PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers.. <i>Expert Opinion on Investigational Drugs</i> , 2022 ,	5.9	1
122	Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or Alteration. <i>Cancers</i> , 2021 , 13,	6.6	1
121	LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers. <i>Oncogenesis</i> , 2021 , 10, 40	6.6	
120	Phase I safety and efficacy study of autophagy inhibition with hydroxychloroquine to augment the antiproliferative and biological effects of preoperative palbociclib plus letrozole for estrogen receptor-positive, HER2-negative metastatic breast cancer (MBC).. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1067-1067	2.2	0
119	Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. <i>Annals of Surgery</i> , 2021 , 274, e150-e159	7.8	3
118	Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2020 , 40, 115-126	7.1	4
117	Cytoplasmic Cyclin E Is an Independent Marker of Aggressive Tumor Biology and Breast Cancer-Specific Mortality in Women over 70 Years of Age. <i>Cancers</i> , 2020 , 12,	6.6	2
116	Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer. <i>British Journal of Cancer</i> , 2020 , 122, 812-822	8.7	4
115	Abstract PD2-05: Differential mechanisms of acquired resistance to abemaciclib versus palbociclib reveal novel therapeutic strategies for CDK4/6 therapy-resistant breast cancers 2020 ,		2
114	Arthur B. Pardee: In Memoriam (1921-2019). <i>Cancer Research</i> , 2019 , 79, 2089-2090	10.1	
113	Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 3996-4013	12.9	41
112	Cytoplasmic cyclin E independently predicts recurrence in older patients with primary breast cancer.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3128-3128	2.2	
111	Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis. <i>Genome Research</i> , 2018 , 28, 159-170	9.7	65
110	Histone modification profiling in breast cancer cell lines highlights commonalities and differences among subtypes. <i>BMC Genomics</i> , 2018 , 19, 150	4.5	36
109	Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 741-751	5.9	23
108	Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2018 , 78, 742-757	10.1	58

107	Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions. <i>Targeted Oncology</i> , 2018 , 13, 21-38	5	54
106	Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies. <i>Cancer Research</i> , 2018 , 78, 5481-5491	10.1	24
105	Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. <i>Clinical Cancer Research</i> , 2018 , 24, 6594-6610	12.9	36
104	CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest. <i>Molecular Cancer Therapeutics</i> , 2017 , 16, 1751-1764	6.1	25
103	Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 7288-7300	12.9	20
102	Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. <i>Journal of Cancer</i> , 2017 , 8, 2004-2009	4.5	9
101	CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. <i>Nature Communications</i> , 2017 , 8, 15916	17.4	144
100	AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. <i>Molecular Cancer Research</i> , 2017 , 15, 45-58	6.6	55
99	Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 2991-3002	12.9	33
98	Abstract 2060: Characterizing acquired resistance to palbociclib in breast cancer 2017 ,		2
97	Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. <i>Oncotarget</i> , 2017 , 8, 14897-14911	3.3	28
96	Relationships of cyclin E with clinical outcome and biomarkers in older women with early operable primary breast cancer.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e12031-e12031	2.2	0
95	PKC α promotes ovarian tumor progression through deregulation of cyclin E. <i>Oncogene</i> , 2016 , 35, 2428-2440	9.1	15
94	Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer. <i>American Journal of Pathology</i> , 2016 , 186, 1900-1912	5.8	32
93	PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness. <i>Nature Communications</i> , 2016 , 7, 10633	17.4	48
92	Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 593-607	6.1	39
91	Targeting the Cell Cycle in Breast Cancer. <i>Breast Diseases</i> , 2016 , 27, 256-260		
90	Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion. <i>Cell Cycle</i> , 2016 , 15, 1579-90	4.7	14

89	Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells. <i>Cancer Research</i> , 2016 , 76, 2406-18	10.1	50
88	How will we recruit, train, and retain physicians and scientists to conduct translational cancer research?. <i>Cancer</i> , 2015 , 121, 806-16	6.4	9
87	The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase. <i>Oncogene</i> , 2015 , 34, 3556-67	9.2	19
86	A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. <i>Investigational New Drugs</i> , 2015 , 33, 890-4	4.3	47
85	2SOMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. <i>Nature Communications</i> , 2014 , 5, 3459	17.4	81
84	Indole-3-carbinol and its N-alkoxy derivatives preferentially target ER α -positive breast cancer cells. <i>Cell Cycle</i> , 2014 , 13, 2587-99	4.7	31
83	Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. <i>Breast Cancer Research</i> , 2014 , 16, 3417	8.3	14
82	A phase 1 study of dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple-negative breast cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 163-163	2.2	2
81	Exploiting Cell Cycle Pathways in Cancer Therapy: New (and Old) Targets and Potential Strategies. <i>Cancer Drug Discovery and Development</i> , 2014 , 337-372	0.3	1
80	Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer. <i>Breast Cancer Research</i> , 2013 , 15, R3	8.3	29
79	EVI1 splice variants modulate functional responses in ovarian cancer cells. <i>Molecular Oncology</i> , 2013 , 7, 647-68	7.9	35
78	Staurosporine is chemoprotective by inducing G1 arrest in a Chk1- and pRb-dependent manner. <i>Carcinogenesis</i> , 2013 , 34, 2244-52	4.6	7
77	Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells. <i>Cancer Research</i> , 2013 , 73, 5556-68	10.1	34
76	Targeting low molecular weight cyclin E (LMW-E) in breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012 , 132, 575-88	4.4	30
75	LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. <i>PLoS Genetics</i> , 2012 , 8, e1002538	6	28
74	Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer. <i>Cell Cycle</i> , 2012 , 11, 1468-76	4.7	16
73	Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. <i>Breast Diseases</i> , 2011 , 22, 266-267		
72	MDA-7 results in downregulation of AKT concomitant with apoptosis and cell cycle arrest in breast cancer cells. <i>Cancer Gene Therapy</i> , 2011 , 18, 510-9	5.4	8

71	Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells. <i>Cell Biology and Toxicology</i> , 2011 , 27, 123-31	7.4	4
70	Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E. <i>Cancer Research</i> , 2011 , 71, 3377-86	10.1	41
69	Breaking the cycle: An insight into the role of ER α in eukaryotic cell cycles. <i>Journal of Carcinogenesis</i> , 2011 , 10, 25	1.9	9
68	A novel interaction between HER2/neu and cyclin E in breast cancer. <i>Oncogene</i> , 2010 , 29, 3896-907	9.2	49
67	Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C. <i>Cancer Research</i> , 2010 , 70, 5085-95	10.1	25
66	The neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancer. <i>Cancer Research</i> , 2010 , 70, 7125-36	10.1	20
65	Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. <i>Cancer Research</i> , 2010 , 70, 5074-84	10.1	47
64	Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. <i>Clinical Cancer Research</i> , 2010 , 16, 1179-90	12.9	37
63	Absence of pRb facilitates E2F1-induced apoptosis in breast cancer cells. <i>Cell Cycle</i> , 2010 , 9, 1122-30	4.7	17
62	Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation. <i>Cancer Research</i> , 2009 , 69, 2817-25	10.1	34
61	Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. <i>Cell Cycle</i> , 2009 , 8, 1062-8	4.7	39
60	DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer. <i>PLoS Medicine</i> , 2009 , 6, e1000068	11.6	31
59	Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 3654-62	12.9	109
58	Cyclin E deregulation is an early event in the development of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009 , 115, 651-9	4.4	30
57	Post-translational modification and stability of low molecular weight cyclin E. <i>Oncogene</i> , 2009 , 28, 3167-76	7.6	8
56	Biomarkers in neoadjuvant trials. <i>Cancer Treatment and Research</i> , 2009 , 147, 1-36	3.5	
55	Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. <i>Cancer Research</i> , 2008 , 68, 7966-74	10.1	88
54	Synchronization of the cell cycle using lovastatin. <i>Cell Cycle</i> , 2008 , 7, 2434-40	4.7	56

53	Cyclin E-associated kinase activity predicts response to platinum-based chemotherapy. <i>Clinical Cancer Research</i> , 2007 , 13, 4800-6	12.9	12
52	Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. <i>Cancer Research</i> , 2007 , 67, 7212-22	10.1	58
51	Differential regulation of elafin in normal and tumor-derived mammary epithelial cells is mediated by CCAAT/enhancer binding protein beta. <i>Cancer Research</i> , 2007 , 67, 11272-83	10.1	14
50	The double-stranded RNA-activated protein kinase mediates radiation resistance in mouse embryo fibroblasts through nuclear factor kappaB and Akt activation. <i>Clinical Cancer Research</i> , 2007 , 13, 6032-9	12.9	23
49	Cell cycle deregulation in breast cancer: insurmountable chemoresistance or AchillesSheel?. <i>Advances in Experimental Medicine and Biology</i> , 2007 , 608, 52-69	3.6	5
48	Deregulation of cyclin E meets dysfunction in p53: closing the escape hatch on breast cancer. <i>Journal of Cellular Physiology</i> , 2006 , 209, 686-94	7	23
47	Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway. <i>Cell Cycle</i> , 2006 , 5, 1654-61	4.7	23
46	The differential staurosporine-mediated G1 arrest in normal versus tumor cells is dependent on the retinoblastoma protein. <i>Cancer Research</i> , 2006 , 66, 9744-53	10.1	15
45	Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteasome. <i>Cancer Research</i> , 2006 , 66, 1040-51	10.1	45
44	Cyclin E as a prognostic and predictive marker in breast cancer. <i>Seminars in Cancer Biology</i> , 2005 , 15, 319-26	12.7	51
43	Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. <i>Cancer</i> , 2005 , 104, 1779-80; author reply 1780	6.4	
42	Atypical PKC α contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005 , 102, 12519-24	11.5	206
41	The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. <i>Journal of Biological Chemistry</i> , 2005 , 280, 15148-57	5.4	52
40	The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. <i>Cancer Research</i> , 2005 , 65, 692-7	10.1	42
39	Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cells. <i>Journal of Biological Chemistry</i> , 2004 , 279, 12695-705	5.4	26
38	Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. <i>Cancer Research</i> , 2004 , 64, 3198-208	10.1	121
37	Cyclin E deregulation alters the biologic properties of ovarian cancer cells. <i>Oncogene</i> , 2004 , 23, 2648-57	9.2	52
36	Role of cell cycle in mediating sensitivity to radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004 , 59, 928-42	4	707

35	Low-molecular-weight cyclin E: the missing link between biology and clinical outcome. <i>Breast Cancer Research</i> , 2004 , 6, 188-91	8.3	21
34	The Low Molecular Weight Isoforms of Cyclin E Deregulate the Cell Cycle of Mammary Epithelial Cells. <i>Cell Cycle</i> , 2003 , 2, 459-464	4.7	30
33	Cyclin E and Its Low Molecular Weight Forms in Human Cancer and as Targets for Cancer Therapy. <i>Cancer Biology and Therapy</i> , 2003 , 2, 37-46	4.6	50
32	Cyclin E in breast cancer. <i>New England Journal of Medicine</i> , 2003 , 348, 1063-4; author reply 1063-4	59.2	3
31	Cyclin E is a more powerful predictor of breast cancer outcome than proliferation. <i>Nature Medicine</i> , 2003 , 9, 152	50.5	22
30	The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. <i>Cell Cycle</i> , 2003 , 2, 461-6	4.7	16
29	Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. <i>Cancer Biology and Therapy</i> , 2003 , 2, S38-47	4.6	33
28	Selective protection of normal proliferating cells against the toxic effects of chemotherapeutic agents. <i>Progress in Cell Cycle Research</i> , 2003 , 5, 527-32		16
27	Cyclin E and survival in patients with breast cancer. <i>New England Journal of Medicine</i> , 2002 , 347, 1566-75	59.2	464
26	Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. <i>Oncogene</i> , 2001 , 20, 147-55	9.2	310
25	Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. <i>Molecular and Cellular Biology</i> , 2001 , 21, 6254-69	4.8	159
24	Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. <i>Science</i> , 2001 , 294, 173-7	33.3	650
23	Activation of the estrogen-signaling pathway by p21(WAF1/CIP1) in estrogen receptor-negative breast cancer cells. <i>Journal of the National Cancer Institute</i> , 2000 , 92, 1403-13	9.7	33
22	Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G(0)/G(1) to S phase transition in normal and tumor cells. <i>Nucleic Acids Research</i> , 2000 , 28, 2108-13	20.1	149
21	Novel splice variants of cyclin E with altered substrate specificity. <i>Nucleic Acids Research</i> , 2000 , 28, E101	20.1	38
20	Expression of an estrogen receptor alpha variant protein in cell lines and tumors. <i>Molecular and Cellular Endocrinology</i> , 2000 , 162, 167-80	4.4	12
19	Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1999 , 96, 7797-802	11.5	312
18	UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent. <i>Oncogene</i> , 1999 , 18, 5691-702	9.2	54

17	The biphasic induction of p21 and p27 in breast cancer cells by modulators of cAMP is posttranscriptionally regulated and independent of the PKA pathway. <i>Experimental Cell Research</i> , 1999 , 252, 211-23	4.2	18
16	Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. <i>Oncogene</i> , 1998 , 17, 2393-402	9.2	173
15	Molecular cloning, characterization, and regulation of the human mitochondrial serine hydroxymethyltransferase gene. <i>Journal of Biological Chemistry</i> , 1997 , 272, 1842-8	5.4	102
14	The role of cyclin E in cell proliferation, development and cancer. <i>Progress in Cell Cycle Research</i> , 1997 , 3, 171-91		90
13	Cyclin E, a redundant cyclin in breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1996 , 93, 15215-20	11.5	106
12	Synchronization of mammalian cells by Lovastatin. <i>Cytotechnology</i> , 1996 , 18, 109-114		4
11	Cyclin E -- a better prognostic marker for breast cancer than cyclin D?. <i>Nature Medicine</i> , 1996 , 2, 254	50.5	24
10	Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3S5-dichloroaminopterin. <i>Journal of Medicinal Chemistry</i> , 1994 , 37, 2167-74	8.3	24
9	The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. <i>Cell</i> , 1993 , 75, 805-16	56.2	5067
8	Redundant cyclin overexpression and gene amplification in breast cancer cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993 , 90, 1112-6	11.5	448
7	Transcriptional downregulation of gap-junction proteins blocks junctional communication in human mammary tumor cell lines. <i>Journal of Cell Biology</i> , 1992 , 118, 1213-21	7.3	209
6	Down-regulation of a member of the S100 gene family in mammary carcinoma cells and reexpression by azadeoxycytidine treatment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992 , 89, 2504-8	11.5	130
5	Modification of cell proliferation with inhibitors. <i>Current Opinion in Cell Biology</i> , 1992 , 4, 186-91	9	20
4	Progression through the cell cycle: an overview. <i>The American Review of Respiratory Disease</i> , 1990 , 142, S3-6		4
3	An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1990 , 87, 8950-4	11.5	238
2	Preparation of (6S)-5-formyltetrahydrofolate labeled at high specific activity with ¹⁴ C and ³ H. <i>Methods in Enzymology</i> , 1986 , 122, 309-12	1.7	9
1	Understanding the Biology of Cancer101-122		